Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Farther Finance Advisors LLC

Farther Finance Advisors LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 671 shares of the biopharmaceutical company’s stock after buying an additional 31 shares during the period. Farther Finance Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $710,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after purchasing an additional 91,956 shares during the period. Capital World Investors grew its stake in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares in the last quarter. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the period. Putnam Investments LLC raised its holdings in shares of Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares during the period. Finally, Norges Bank acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $932,571,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $1,184.69 on Tuesday. The stock’s 50-day moving average is $1,105.34 and its two-hundred day moving average is $1,014.78. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The firm has a market cap of $130.54 billion, a price-to-earnings ratio of 35.00, a PEG ratio of 3.13 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $8.79 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Analyst Ratings Changes

REGN has been the subject of several research reports. Piper Sandler lifted their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Argus boosted their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Truist Financial reiterated a “buy” rating and issued a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Finally, Wells Fargo & Company lifted their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,108.45.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,397,202. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Michael S. Brown sold 1,535 shares of the stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,437,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total value of $836,097.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,397,202. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,239 shares of company stock worth $23,933,880. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.